Table 4.
Main prognostic and predictive statistically significant biomarkers reviewed.
| References | Patient population | Biomarker(s) | Sample size | Main findings |
|---|---|---|---|---|
| D' Alterio et al. (41) | mRCC | CXCR4 Negative/Low vs. Mod vs. High expression | 62 | HR for progression in patients treated with sunitinib = 2.04; p = 0.0271 |
| HR for death in patients treated with sunitinib = 1.48 (95%CI = 0.93–2.38); p = 0.0974 | ||||
| Motzer et al. (43) | advanced RCC | HIF1a low vs. high expression | 292 | HR for progression in patients treated with sunitinib = 1.55; p = 0.0341 |
| HR for death in patients treated with sunitinib = 1.34; p = 0.2095 | ||||
| Rini et al. (51) | mRCC | sVEGFR-3 less than median baseline value vs. greater than median serum levels | 59 | HR for progression in patients treated with sunitinib = 0.45; p = 0.006 |
| VEGF-C less than median baseline value vs. greater than median serum levels | 57 | HR for progression in patients treated wit sunitinib = 0.37; p = 0.0006 | ||
| Tran et al. (53) | mRCC | Interleukin 6 low serum levels | 344 | HR for progression in patients treated with pazopanib vs. interferon = 0.55; p = 0.009 |
| Interleukin 6 high serum levels | HR for progression in patients treated with pazopanib vs. interferon = 0.31; p = 0.009 | |||
| Interleukin 6 low serum levels | HR for death in patients treated with pazopanib vs. interferon = 1.41; p = 0.005 | |||
| Interleukin 6 high serum levels | HR for death in patients treated with pazopanib vs. interferon = 0.42; p = 0.005 | |||
| Interleukin 8 low serum levels | HR for death in patients treated with pazopanib vs. interferon = 1.49; p = 0.002 | |||
| Interleukin 8 high serum levels | HR for death in patients treated with pazopanib vs. interferon = 0.42; p = 0.002 | |||
| Osteopontin low serum levels | HR for death in patients treated with pazopanib vs. interferon = 0.96; p = 0.033 | |||
| Osteopontin high serum levels | HR for death in patients treated with pazopanib vs. interferon = 0.41; p = 0.033 | |||
| VEGF low serum levels | HR for death in patients treated with pazopanib vs. interferon = 1.2; p = 0.006 | |||
| VEGF high serum levels | HR for death in patients treated with pazopanib vs. interferon = 0.41; p = 0.006 | |||
| Peña et al. (62) | Advanced RCC | VEGF high vs. low expression | 348 | HR for death in patients treated with sorafenib = 1.64; p = 0.0027 |
| CAIX high vs. low expression | 66 | HR for death in patients treated with sorafenib = 2.26; p = 0.034 | ||
| TIMP-1 high vs. low expression | 63 | HR for death in patients treated with sorafenib = 3.34; p = 0.001 | ||
| Ras p21 high vs. low expression | 65 | HR for death in patients treated with sorafenib = 2.49; p = 0.016 | ||
| Xu et al. (72) | Advanced/mRCC | IL8 2767TT genotype vs. IL8 wild-type AA genotype | 397 | HR for progression in patients treated with pazopanib = 1.8; p = 0.009 |
| IL8 251AA genotype vs. IL8 wild-type TT genotype | HR for progression in patients treated with pazopanib = 1.7; p = 0.01 | |||
| HIF1a 1790AG genotype vs. HIF1a wild type GG genotype | HR for progression in patients treated with pazopanib = 1.8; p = 0.03 | |||
| Xu et al. (74) | Advanced RCC | IL8 rs1126647 polymorphism, variant T allele vs. reference variant A | 186 | HR for death in patients treated with pazopanib = 1.45; p = 0.007 |
| 337 | HR for death in patients treated with sunitinib = 1.39; p = 0.008 | |||
| 88 | HR for death in patients treated with sunitinib = 1.62; p = 0.034 | |||
| Garcia-Donas et al. (75) | Advanced RCC | VEGFR3 rs307826 AA variant vs. AG varian | 95 | HR for progression in patients treated with sunitinib = 3.57; p = 0.0079 |
| VEGFR3 rs307821 GG variant vs. GT variant | HR for progression in patients treated with sunitinib = 3.31 (95% CI = 1.64–6.68); p = 0.014 | |||
| van der Veldt et al. (77) | mRCC | ABCB1 other haplotypes vs. TCG haplotype | 129 | HR for progression in patients treated with sunitinib = 0.52; p = 0.033 |
| CYP3A5 6986A/G GG haplotype vs. AG+AA haplotypes | 128 | HR for progression in patients treated with sunitinib = 0.26; p = 0.032 | ||
| Escudier et al. (78) | mRCC | VEGFR2 rs2071559 AA variant vs. GG variant | 141 | HR for progression in patients treated with sorafenib = 2.22; p = 0.0053 |
| VEGFR2 rs2071559 AA variant vs. GG variant | HR for death in patients treated with sorafenib = 2.58; p = 0.0027 | |||
| VEGFR2 rs1870377 TT variant vs. TA variant | 47 | HR for progression in patients treated with sorafenib = 0.62; p = 0.026 | ||
| HIF-1α rs11549465 CC variant vs. CT variant | 33 | HR for progression in patients treated with axitinib = 1.93; p = 0.006 | ||
| HR for death in patients treated with axitinib = 1.88; p = 0.007 | ||||
| VEGF-A rs699947 CC variant vs. AA variant | 42 | HR for death in patients treated with axitinib = 0.39; p = 0.001 |
mRCC, metastatic renal cell carcinoma; VEGF, vascular endothelial growth factor; CXCR, chemokine receptor; HIF, hypoxia-inducible factors; VEGFR, vascular endothelial growth factor receptor; TIMP−1, metallopeptidase inhibitor 1; KDR, kinase insert domain receptor; CAIX, Carbonic Anhydrase IX; IL, interleukin; ABCB1, ATP binding cassette subfamily B member 1; CYP3A5, cytochrome P450 family 3 subfamily A member; ABCG2, ATP-binding cassette super-family G member.